Fig. 1From: Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)Phenotypic and genomic biomarkers associated with clinical benefit from anti-PD-1/PD-L1 therapyBack to article page